About Neil Martin
There is increasing promise in the clinic for using targeted treatments for prostate cancer. Because of the specificity of emerging pharmacologic agents, it will be important to identify and treat men who are most likely to respond to these medications. Dr. Martin is currently developing a new diagnostic platform on clinical biopsies. His work is directed at assessing activation of a specific signaling system in prostate cancer cells—the PI3K pathway—with an aim to produce a simple test to identify men most likely to benefit from this new class of targeted medicines. There are several new PI3K pathway drugs entering the clinic in adult oncology in 2010. The overall goal of this work is to further refine individualized treatment strategies for men with advanced prostate cancer.
The 2010 David Epstein – PCF Young Investigator Award
Neil Martin, MD, MPH
Dana-Farber Cancer Institute and Brigham and Women’s Hospital – Boston, MA
Massimo Loda, MD, Professor of Pathology, Harvard Medical School.